for watchlist

BioPulse (WKN 917016) hat sich zuletzt durch zwei erfahrene Manager personell weiter verstärkt, so die Analysten von Bluebull.

Man stehe offenbar kurz vor einer Fusion mit der Aidan Inc.. Zudem plane das Unternehmen ein Listing an der American Stock Exchange, was sich sicherlich positiv auf den Kurs auswirken würde. Die Vermarktung des Krebsdiagnosetests solle zügig voranschreiten. Gemäß den Ausführungen des CEO koste der Test pro Patient 50 Cents, solle jedoch für 10 bis 20 $ verkauft werden. Hier ergebe sich demnach ein unglaubliches Umsatz- und Gewinnpotenzial.

erinnere mich nochmals, habe nämlich heute/morgen fast keine Zeit

sorry - habe zwar kurz daran gedacht - aber dennoch vergessen. ich werde es nachholen, hatte auch einiges zu tun - aber wie gesagt - vergessen.

Möchte heute noch ein bisschen an der NAsdaq traden - villeicht geht es mal zwischendurch.

haha

@HAHAHA ich helf dir ein bischen :-)

BioPulse Appoints 12 Year XOMA Veteran as CFO  
       FRIDAY, FEBRUARY 02, 2001 5:00 AM
- PRNewswire

SAN YSIDRO, Calif., Feb 2, 2001 /PRNewswire via COMTEX/ -- BioPulse International, Inc., (OTC Bulletin Board: BIOP; Frankfurt: BPZ) today announced the appointment of John M. Allen as the company's chief financial officer. Allen brings over 20 years of extensive experience and accomplishments in finance and management including, a 12 year tenure with XOMA Corporation, where he was controller and responsible for all treasury and financial reporting and analysis. In addition, Allen was the Audit Senior, CPA at Deloitte & Touche, and holds an MBA in finance and accounting from the University of California, Berkeley.

About BioPulse

This fast growing, profitable, San Diego based Biotech company is combining alternative and biotech treatments for cancer and other diseases. The company owns a compelling portfolio of proprietary therapeutics and diagnostics that are the subject of trials at clinics outside the United States, which offer a comprehensive array of state-of-the-art procedures.

NOTE: Various statements made within this press release may constitute "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectations.

CONTACT: John Liviakis of Liviakis Financial Communications, Inc., 415-389-4670, or fax, 415-389-4694, or moreinfo@lfcnet.com, for BioPulse International, Inc./

Dr. Soule is a Director for three privately held firms, Oncology.com, a vertical Internet cancer enterprise supplying the needs of cancer patients and their physicians and Miavita, a premier health and wellness company and CanFite Biopharmaceuticals, a cancer drug discovery and development firm. He is also a member of the Scientific Advisory Boards of two biotechnology firms, Corvas International and Activx Biosciences and is an executive advisor to MedBroadcasting, Inc. Dr. Soule is a member of the Visiting Committee for the Lank Genitourinary Oncology at the Dana-Farber Cancer Institute.

The addition of Dr. Soule to the Board of Directors will replace director Stephen Fey. The number of seats will remain the same at 7. BioPulse thanks Mr. Fey for his outstanding contributions and wishes him well on his new endeavors.

BioPulse Successfully Completes $3 Million Dollar Equity Financing  
       WEDNESDAY, FEBRUARY 07, 2001 5:00 AM
- PRNewswire

SAN DIEGO, Feb 7, 2001 /PRNewswire via COMTEX/ -- BioPulse International, Inc., (OTC Bulletin Board: BIOP; Frankfurt: BPZ) today announced the successful completion of a $3 million dollar bridge financing. The terms were not disclosed. President Loran Swensen commented, "Although a relatively small financing for a life science company, this does several key things for us. 1) We fulfilled our final obligation to Aidan Labs, Inc. in our critical partnership agreement that gives BioPulse worldwide exclusive rights to the exciting angiogenesis, dendritic cancer cell vaccine, immune stimulant, and cytokine formulation products we have previously announced; 2) we can expand our vaccine production capacity to accommodate our record backlog in our new seventeen thousand square foot facility located at 8940 Kenamar Drive, San Diego; 3) this financing now completes the final criteria for our AMEX listing which is now expected soon; 4) although we've had very little debt, this will significantly improve our shareholder's equity, working capital, and ratios